ロード中...
Deferasirox, an oral iron chelator, prevents hepatocarcinogenesis and adverse effects of sorafenib
Although sorafenib is expected to have a chemopreventive effect on hepatocellular carcinoma (HCC) recurrence, there are limitations to its use because of adverse effects, including effects on liver function. We have reported that the iron chelator, deferoxamine can prevent liver fibrosis and preneop...
保存先:
| 出版年: | J Clin Biochem Nutr |
|---|---|
| 主要な著者: | , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
the Society for Free Radical Research Japan
2016
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4865599/ https://ncbi.nlm.nih.gov/pubmed/27257345 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3164/jcbn.15-127 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|